Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kalvista Pharmaceuticals Inc (NQ: KALV ) 9.460 -0.190 (-1.97%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 201,884 Open 9.720 Bid (Size) 3.800 (2) Ask (Size) 10.28 (1) Prev. Close 9.650 Today's Range 9.451 - 9.830 52wk Range 7.210 - 16.88 Shares Outstanding 34,233,643 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference September 10, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Appoints Brian Piekos as Chief Financial Officer September 10, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Performance YTD -22.14% -22.14% 1 Month -27.57% -27.57% 3 Month -18.10% -18.10% 6 Month -14.85% -14.85% 1 Year -1.25% -1.25% More News Read More KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 September 06, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update September 05, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 04, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema September 03, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium August 29, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema August 15, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday July 12, 2024 Via Benzinga KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024 July 11, 2024 Via InvestorPlace KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results July 11, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11 June 27, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema June 18, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024 June 06, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 04, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 June 03, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema May 31, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024 May 24, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present at Upcoming Investor Conferences May 21, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year May 01, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors April 22, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.